Interleukin-17A Antagonist [EPC] - N0000191495
Pharmacologic Class Information
| Pharmacologic Code | N0000191495 |
| Pharmacologic Name | Interleukin-17A Antagonist |
| Pharmacologic Uses |
|
| Pharmacologic Concept | Established Pharmacologic Classes - [EPC] |
| Pharmacologic Concept Description | An established pharmacologic class is a term or phrase that is scientifically valid
and clinically meaningful according to the following definitions:
|
NDC Products with Interleukin-17A Antagonist
The table contains 8 products whose active ingredient are classified under the same pharmacologic class Interleukin-17A Antagonist [EPC].
| NDC | Proprietary Name | Non-Proprietary Name | Dosage Form | Route Name | Company Name | Status | |
|---|---|---|---|---|---|---|---|
| 0002-7724 | Taltz | Non-Proprietary Name: Ixekizumab | Injection, Solution | Subcutaneous | Eli Lilly And Company | ACTIVE | |
| 0078-1168 | Cosentyx | Non-Proprietary Name: Secukinumab | Injection, Solution, Concentrate | Intravenous | Novartis Pharmaceuticals Corporation | ACTIVE | |
| 0078-0639 | Cosentyx | Non-Proprietary Name: Secukinumab | Injection | Subcutaneous | Novartis Pharmaceuticals Corporation | ACTIVE | |
| 0078-1070 | Cosentyx | Non-Proprietary Name: Secukinumab | Injection | Subcutaneous | Novartis Pharmaceuticals Corporation | ACTIVE | |
| 0078-1056 | Cosentyx | Non-Proprietary Name: Secukinumab | Injection | Subcutaneous | Novartis Pharmaceuticals Corporation | ACTIVE | |
| 0002-8900 | Taltz | Non-Proprietary Name: Ixekizumab | Injection, Solution | Subcutaneous | Eli Lilly And Company | ACTIVE | |
| 0002-8905 | Taltz | Non-Proprietary Name: Ixekizumab | Injection, Solution | Subcutaneous | Eli Lilly And Company | ACTIVE | |
| 0002-1445 | Taltz | Non-Proprietary Name: Ixekizumab | Injection, Solution | Subcutaneous | Eli Lilly And Company | ACTIVE |